Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

2.9K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extending the prognostic value of red cell distribution width to nodal T follicular helper cell lymphoma.

Leukemia & lymphoma·2026
Same author

Impact of Transplant Type on Infection Risk in Studies of Neutropenic Diets.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Treatment-specific differences in soluble B-cell maturation antigen levels at minimum residual disease negativity in multiple myeloma.

British journal of haematology·2026
Same author

Patient selection and treatment sequencing in RESMAIN.

The Lancet. Haematology·2026
Same author

Case Report: Secondary neurolymphomatosis successfully treated with sequential Bruton's tyrosine kinase inhibitor and bispecific antibody therapy.

Frontiers in oncology·2026
Same author

Progression of diabetic nephropathy and adverse renal outcomes: possible involvement of Toll-like receptor 4 expression.

Clinical and experimental nephrology·2026

Related Experiment Video

Updated: Feb 21, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

7.0K

Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive

Akihiro Kitadate1,2, Sho Ikeda1, Fumito Abe1

  • 1Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine.

Haematologica
|October 14, 2017
PubMed
Summary

Histone deacetylase inhibitors reduce CCR4 expression in T-cell lymphomas, potentially impacting mogamulizumab efficacy. Pre-treatment with these inhibitors may not be optimal for synergistic effects in CCR4-positive lymphomas.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.9K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K

Related Experiment Videos

Last Updated: Feb 21, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

7.0K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.9K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Histone deacetylase inhibitors (HDACi) show promise for T-cell lymphomas.
  • CCR4 is a therapeutic target, with mogamulizumab demonstrating efficacy.
  • Understanding drug interactions is crucial for optimizing T-cell lymphoma treatment.

Purpose of the Study:

  • To investigate the in vitro synergistic effects of mogamulizumab and HDAC inhibitors on T-cell lymphomas.
  • To determine the role of specific histone deacetylase (HDAC) isoforms in regulating CCR4 expression.
  • To evaluate the impact of HDAC inhibitor pre-treatment on mogamulizumab efficacy.

Main Methods:

  • Examined CCR4 mRNA and surface expression in T-cell lymphoma cell lines.
  • Utilized pan-HDAC and isoform-specific HDAC inhibitors, alongside short-interfering RNA (siRNA) for knockdown studies.
  • Assessed CCR4 expression in patient skin samples before and after vorinostat treatment.
  • Performed antibody-dependent cell-mediated cytotoxicity (ADCC) assays with mogamulizumab.

Main Results:

  • Vorinostat, a pan-HDAC inhibitor, downregulated CCR4 expression in T-cell lymphoma cell lines and patient samples.
  • Romidepsin, a class I selective HDAC inhibitor, most efficiently reduced CCR4.
  • HDAC2 knockdown significantly reduced CCR4 expression, indicating its primary regulatory role.
  • Mogamulizumab efficacy was reduced when lymphoma cells were pre-treated with vorinostat.

Conclusions:

  • HDAC2 is a key regulator of CCR4 expression in T-cell lymphomas.
  • Pre-treatment with HDAC inhibitors may diminish the therapeutic efficacy of mogamulizumab.
  • Optimal therapeutic sequencing of HDAC inhibitors and mogamulizumab requires careful consideration for CCR4-positive T-cell lymphomas.